Skip to main content

Table 1 Patients’ characteristics

From: Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitroand prospective clinical study

Patient

Age (years)

Sex

Site

Previous surgeries

Infection duration (months)

Pathogenesis

Stage

Host type

1

35

F

Tibia

3

12

Post-traumatic

4

A

2

50

M

Femur

5

60

Post-traumatic

3

B (smoker)

3

60

M

Femur

2

18

Haematogenous

1

B (lymphoma, chemotherapy)

4

47

M

Tibia

4

54

Haematogenous

1

C (smoker, vasculopathy, diabetes)

5

35

M

Femur

1

18

Post-traumatic

3

A

6

23

M

Tibia

1

9

Post-surgical

3

A

7

80

M

Tibia

3

38

Post-surgical

3

B (psoriasis, corticosteroids)

8

41

M

Tibia

2

12

Post-surgical

3

A

9

38

M

Femur

1

36

Post-surgical

3

A

10

28

M

Femur

1

12

Post-surgical

3

A

11

40

F

Femur

1

12

Post-traumatic

3

B (tumor, radiotherapy)

12

50

F

Humerus

0

10

Haematogenous

1

B (rheumatoid arthritis)

13

40

F

Tibia

3

24

Post-traumatic

2

B ( peripheral vasculopathy)

14

60

M

Tibia

2

12

Post-traumatic

4

B (smoker)

15

44

M

Tibia

3

24

Post-traumatic

3

B (smoker, alcol abuse)

16

36

F

Tibia

0

6

Haematogenous

1

A

17

55

M

Tibia

2

12

Post-surgical

3

B (smoker, peripheral vasculopathy)

18

20

M

Tibia

0

6

Haematogenous

1

A

19

36

M

Tibia

2

6

Post-surgical

3

A

20

40

M

Femur

2

12

Post-surgical

3

B (smoker, peripheral vasculopathy)

21

30

M

Tibia

0

10

Haematogenous

1

B (tetraplegia, recurrent pneumonia and urinary tract infection)

22

50

F

Tibia

2

24

Post-traumatic

3

B (smoker)

23

52

F

Tibia

2

12

Haematogenous

1

B (diabetes, peripheral neuropathy)

24

50

M

Tibia

2

12

Post-surgical

3

B (Churg-Strauss disease, immunosuppression)

25

61

F

Foot

2

12

Post-surgical

3

B (diabetes)

26

60

M

Tibia

2

6

Post-traumatic

3

B (smoker)

27

20

F

Tibia + Femur

0

12

Haematogenous

1

B (immunosuppressive therapy)